10:00 AM EDT, 08/07/2025 (MT Newswires) -- Akebia Therapeutics ( AKBA ) shares were down more than 17% in early Thursday trading after the company reported breakeven Q2 net income, swinging from a loss of $0.04 per share a year earlier.

Analysts polled by FactSet expected a loss of $0.02.

Revenue for the quarter ended June 30 was $62.5 million, up from $43.6 million a year earlier.

Analysts surveyed by FactSet expected $47.2 million.

The company said it had about $137.3 million in cash and cash equivalents as of June 30.

Price: 3.13, Change: -0.66, Percent Change: -17.44